BLIS Technology forecasts wider 2013 loss, seeks to raise capital
By Hannah Lynch
Aug 31 (BusinessDesk) - BLIS Technologies, the NZX-listed biotechnology company, widened its forecast 2013 loss and launched a share purchase plan and placement to raise up to $1.5 million.
The Dunedin-based company said its operating loss in the year ending March 31 may be $1.3 million, up from the loss of $800,000 million it affirmed in July. The change reflects BLIS's decision to suspend the promotion and sales of its patented K12 probiotic in the US and China and M18 in the US. It is also undertaking a review of its distributor, Stratum Nutrition.
BLIS will also undertake a share purchase plan and placement, with the potential to raise up to $1.5 million. That's on top of investment bank Murray & Co capital raising initiatives released under a confidential information memorandum in April.
"Murray & Co are talking to a number of funds about options to get funds into the business," Bevan Wallace, director told BusinessDesk. "They are progressing well with those discussions - in the interim the board decided we should progress with the share placement plan."
Documentation on the share purchase plan will be provided to shareholders later this month.
BLIS shares fell about 17 percent to 1 cent on the NZX today and have dropped 59 percent this year.